Iraj Sabahi, MD
Rheumatology · Turlock, CANPI 1881886042
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $33,604 of the $51,214 with a category attached, or 65.6%. Amgen accounts for 77.0% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2022 at $17,878 and has fallen 87.6% since, to $2,221 in 2025. Among rheumatology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 671 payments — averaging $76.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$39K
- Johnson & Johnson$3K
- AbbVie$2K
- Mallinckrodt Hospital Products Inc.$1K
- Boehringer Ingelheim$965
- AstraZeneca$954
- plus $5K from 31 others
Across 8 payments — averaging $16,705 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mallinckrodt Hospital Products Inc.$125K
- AbbVie$8K
- Novartis$908
What the payments were for
- Consulting fees$1,9184%
- Speaking & faculty fees$33,60466%
- Grants$2400%
- Travel & lodging$2,4675%
- Food & beverage$12,90425%
- Education$820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 238 | $39,444 |
| Johnson & Johnson(2 entities) | 40 | $2,592 |
| AbbVie | 47 | $1,603 |
| Mallinckrodt Hospital Products Inc. | 58 | $1,120 |
| Boehringer Ingelheim | 32 | $965 |
| AstraZeneca(2 entities) | 37 | $954 |
| E.r. Squibb & Sons, L.L.C. | 43 | $756 |
| GSK | 33 | $717 |
| Novartis | 32 | $575 |
| UCB, Inc. | 19 | $541 |
| Aurinia Pharma U.S., Inc. | 17 | $340 |
| Corcept Therapeutics | 9 | $229 |
| Mallinckrodt Enterprises LLC | 13 | $208 |
| Radius Health, Inc. | 6 | $123 |
| Hikma Pharmaceuticals USA | 6 | $114 |
| Bayer | 3 | $111 |
| Pacira Therapeutics, Inc. | 4 | $89 |
| Gilead | 4 | $77 |
| Octapharma USA, Inc. | 3 | $76 |
| Genentech USA, Inc. | 3 | $60 |
| ANI Pharmaceuticals, Inc. | 3 | $58 |
| Fidia Pharma USA Inc. | 2 | $47 |
| Tersera Therapeutics LLC | 2 | $46 |
| Lilly USA, LLC | 2 | $44 |
| Scilex Pharmaceuticals Inc. | 2 | $40 |
| Antares Pharma, Inc. | 2 | $40 |
| Mindray DS USA, Inc. | 1 | $40 |
| Biocon Biologics Inc | 1 | $32 |
| Kyowa Kirin, Inc. | 1 | $30 |
| Orthogenrx Inc. | 1 | $23 |
| Bioventus LLC | 1 | $22 |
| Organon | 1 | $22 |
| Sanofi | 1 | $20 |
| Qiagen, LLC | 1 | $18 |
| Merck | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,214 in reported general payments places this provider in the 90th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 15 | $619,946 |
| Mycophenolate Mofetil | 28 | $5,135 |
| Hydroxychloroquine Sulfate | 100 | $4,012 |
| Febuxostat | 30 | $3,947 |
| MethotrexateMethotrexate Sodium | 150 | $3,445 |
| Leflunomide | 48 | $3,211 |
| Colchicine | 21 | $1,671 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 43 | $1,590 |
| Prednisone | 129 | $1,161 |
| Allopurinol | 31 | $783 |
| Duloxetine Hcl | 27 | $630 |
| Sulfasalazine | 38 | $502 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $460 |
| Gabapentin | 32 | $370 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 25 | $316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $1,120 | $619,94615 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $40 | $1,67121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 808 rheumatology providers in California.
Other rheumatology in Turlock
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.